Systematic literature review of the health economic implications of early detection by screening populations at risk for type 2 diabetes

References

• IDF Diabetes Atlas. Across the Globe, 7th edn. 2015. Available at: http://www.diabetesatlas.org/across-the-globe.html [Last accessed 6 September 2016]
   Google Scholar
• Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of undiagnosed diabetes in adults. Diabetes Res Clin Pract 2014;103:150-60
   PubMed Web of Science ®Google Scholar
• Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care 1992;15:815-19
   PubMed Web of Science ®Google Scholar
• Gillett M, Brennan A, Watson P, et al. The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study. Health Technol Assess 2015;19:1-80
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Preventing type 2 diabetes: risk identification and interventions for individuals at high risk. NICE Public Health Guidance PH38. London: NICE, 2012. Available at: http://www.nice.org.uk/guidance/ph38 [Last accessed 20 December 2015]
   Google Scholar
• American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care 2016;39(Suppl1):S13-S22
   Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. BMI: preventing ill health and premature death in black, Asian and other minority ethnic groups. NICE Public Health Guidance PH46. London: NICE, 2013. Available at: http://www.nice.org.uk/guidance/ph46 [Last accessed 20 August 2016]
   Google Scholar
• Diabetes UK. Diabetes in the UK 2012 – key statistics on diabetes, 2012. Available at: https://www.diabetes.org.uk/diabetes-in-the-uk-2012 [Last accessed 6 September 2016]
   Google Scholar
• US Preventive Services Task Force (USPSTF). Final recommendation statement abnormal blood glucose and type 2 diabetes mellitus screening, 2015. Available at: http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/screening-for-abnormal-blood-glucose-and-type-2-diabetes [Last accessed 19 August 2016]
   Google Scholar
• Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005;143:251-64
   PubMed Web of Science ®Google Scholar
• US Preventive Services Task Force (USPSTF). Grade definitions, 2015. Available at: http://www.uspreventiveservicestaskforce.org/Page/Name/grade-definitions [Last accessed 31 August 2016]
   Google Scholar
• Waugh N, Scotland G, McNamee P, et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess 2007;11:iii-106
   Web of Science ®Google Scholar
• Franciosi M, De Berardis G, Rossi MCE, et al. Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-term Outcomes Observational) Study. Diabetes Care 2005;28:1187-94
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW. Methods for the economic evaluation of health care programs, 3rd edn. New York: Oxford University Press, 2005
   Google Scholar
• Hoerger TJ, Harris R, Hicks KA, et al. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 2004;140:689-99
   PubMed Web of Science ®Google Scholar
• CDC Diabetes Cost-Effectiveness Study Group Centers for Disease Control and Prevention. The cost-effectiveness of screening for type 2 diabetes. JAMA 1998;280:1757-63
   PubMed Web of Science ®Google Scholar
• Chen THH, Yen MF, Tung TH. A computer simulation model for cost-effectiveness analysis of mass screening for type 2 diabetes mellitus. Diabetes Res Clin Pract 2001;54:S37-42
   PubMed Web of Science ®Google Scholar
• Watson P, Preston L, Squires H, et al. Modelling the economics of type 2 diabetes mellitus prevention: a literature review of methods. Appl Health Econ Health Policy 2014;12:239-53
   PubMedGoogle Scholar
• US Preventive Services Task Force (USPSTF). Diabetes prevention and control: combined diet and physical activity promotion programs to prevent type 2 diabetes among people at increased risk. Included studies – economic review, 2015. Available at: http://www.thecommunityguide.org/diabetes/supportingmaterials/IScombineddietandpa-econ.html [Last accessed 20 August 2016]
   Google Scholar
• Weile LK, Kahn JG, Marseille E, et al. Global cost-effectiveness of GDM screening and management: current knowledge and future needs. Best Pract Res Clin Obstet Gynaecol 2015;29:206-24
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097
   PubMed Web of Science ®Google Scholar
• Icks A, Haastert B, Gandjour A, et al. Cost-effectiveness analysis of different screening procedures for type 2 diabetes: the KORA survey 2000. Diabetes Care 2004;27:2120-8
   PubMed Web of Science ®Google Scholar
• Chung S, Azar KMJ, Baek M, et al. Reconsidering the age thresholds for type II diabetes screening in the US. Am J Prev Med 2014;47:375-81
   PubMed Web of Science ®Google Scholar
• Einarson TR, Bootman JL, Larson LN, McGhan WF. Blood level testing in a community pharmacy: consumer demand and financial feasibility. Am Pharm 1988;NS28:188-91
   Google Scholar
• Husereau D, Drummond M, Petrou S. Consolidated health economic evaluation reporting standards (CHEERS) – explanation and elaboration: a report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. Value Health 2013;16:231-50
   PubMed Web of Science ®Google Scholar
• Basu S, Millett C, Vijan S, et al. The health system and population health implications of large-scale diabetes screening in India: a microsimulation model of alternative approaches. PLoS Med 2015;12:e1001827
   PubMed Web of Science ®Google Scholar
• Zhang P, Engelgau MM, Valdez R, et al. Costs of screening for pre-diabetes among U.S. adults. Diabetes Care 2003;26:2536-42
   PubMed Web of Science ®Google Scholar
• Zhang P, Engelgau MM, Valdez R, et al. Efficient cutoff points for three screening tests for detecting undiagnosed diabetes and pre-diabetes: an economic analysis. Diabetes Care 2005;28:1321-5
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sun J, Pang Z, et al. Evaluation of two screening methods for undiagnosed diabetes in China: a cost-effectiveness study. Prim Care Diabetes 2013;7:275-82
   PubMed Web of Science ®Google Scholar
• Chen L, Magliano DJ, Balkau B, et al. Maximizing efficiency and cost-effectiveness of type 2 diabetes screening: the AusDiab study. Diabet Med 2011;28:414-23
   PubMed Web of Science ®Google Scholar
• Colagiuri S, Walker AE. Using an economic model of diabetes to evaluate prevention and care strategies in Australia. Health Aff 2008;27:256-68
   Web of Science ®Google Scholar
• Dalsgaard EM, Christensen JO, Skriver MV, et al. Comparison of different stepwise screening strategies for type 2 diabetes: finding from Danish general practice, Addition-DK. Prim Care Diabetes 2010;4:223-9
   PubMed Web of Science ®Google Scholar
• Gillies CL, Lambert PC, Abrams KR, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ 2008;336:1180-4
   PubMed Web of Science ®Google Scholar
• Glümer C, Yuyun M, Griffin S, et al. What determines the cost-effectiveness of diabetes screening? Diabetologia 2006;49:1536-44
   PubMed Web of Science ®Google Scholar
• Irvine L, Barton GR, Gasper AV, et al. Cost-effectiveness of a lifestyle intervention in preventing type 2 diabetes. Int J Technol Assess Health Care 2011;27:275-82
   PubMed Web of Science ®Google Scholar
• Johnson SL, Tabaei BP, Herman WH. The efficacy and cost of alternative strategies for systematic screening for type 2 diabetes in the U.S. population 45-74 years of age. Diabetes Care 2005;28:307-10
   PubMed Web of Science ®Google Scholar
• Kahn R, Alperin P, Eddy D, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010;375:1365-74
   PubMed Web of Science ®Google Scholar
• Khunti K, Gillies CL, Taub NA, et al. A comparison of cost per case detected of screening strategies for type 2 diabetes and impaired glucose regulation: modelling study. Diabetes Res Clin Pract 2012;97:505-13
   PubMed Web of Science ®Google Scholar
• Krass I, Mitchell B, Clarke P, et al. Pharmacy diabetes care program: analysis of two screening methods for undiagnosed type 2 diabetes in Australian community pharmacy. Diabetes Res Clin Pract 2007;75:339-47
   PubMed Web of Science ®Google Scholar
• Lee DS, Remington P, Madagame J, Blustein J. A cost analysis of community screening for diabetes in the central Wisconsin medicare population: results from the metastar pilot project in Wausau. Wis Med J 2000;99:39-43
   Google Scholar
• Liu X, Li C, Gong H, et al. An economic evaluation for prevention of diabetes mellitus in a developing country: A modelling study. BMC Public Health 2013;13:729
   PubMed Web of Science ®Google Scholar
• Mohan V, Goldhaber-Fiebert JD, Radha V, Gokulakrishnan K. Screening with OGTT alone or in combination with the Indian diabetes risk score or genotyping of TCF7L2 to detect undiagnosed type 2 diabetes in Asian Indians. Indian J Med Res 2011;133:294-9
   PubMed Web of Science ®Google Scholar
• Mortaz S, Wessman C, Duncan R, et al. Impact of screening and early detection of impaired fasting glucose tolerance and type 2 diabetes in Canada: a Markov model simulation. Clinicoecon Outcomes Res 2012;4:91-7
   PubMedGoogle Scholar
• Schaufler TM, Wolff M. Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in Germany. Appl Health Econ Health Policy 2010;8:191-202
   PubMedGoogle Scholar
• Srichang N, Jiamjarasrangsi W, Aekplakorn W, Supakankunti S. Cost and effectiveness of screening methods for abnormal fasting plasma glucose among Thai adults participating in the annual health check-up at King Chulalongkorn Memorial Hospital. J Med Assoc Thai 2011;94:833-41
   PubMedGoogle Scholar
• Toscano CM, Zhuo X, Imai K, et al. Cost-effectiveness of a national population-based screening program for type 2 diabetes: the Brazil experience. Diabetol Metab Syndr 2015;7:95
   PubMed Web of Science ®Google Scholar
• Wu EL, Kazzi NG, Lee JM. Cost-effectiveness of screening strategies for identifying pediatric diabetes mellitus and dysglycemia. Arch Pediatr Adolesc Med 2013;167:32-9
   Google Scholar
• World Health Organization. Cost effectiveness and strategic planning (WHO-CHOICE), 2014. Available at: http://www.who.int/choice/cost-effectiveness/en/[Last accessed 15 January 2016].
   Google Scholar
• Hayes AJ, Leal J, Gray AM, et al. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 2013;56:1925-33
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 1996;276:1409-15
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Prospective Diabetes Study (UKPDS), VIII: study design, progress and performance. Diabetologia 1991;34:877-90
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12
   PubMed Web of Science ®Google Scholar
• Dunstan DW, Zimmett PZ, Welborn TA. The Australian diabetes, obesity and lifestyle study (AusDiab) – methods and response rates. Diabetes Res Clin Pract 2002;57:119-29
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-9
   PubMed Web of Science ®Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59
   PubMed Web of Science ®Google Scholar
• Rasmussen SS, Glümer C, Sandbaek A, et al. Progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screening programme in general practice: the ADDITION Study, Denmark. Diabetologia 2007;50:293-7
   PubMed Web of Science ®Google Scholar
• Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101:671-9
   PubMed Web of Science ®Google Scholar
• Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 1998;21:518-24
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG, et al. HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62
   PubMed Web of Science ®Google Scholar
• Rathmann W, Haastert B, Icks A, et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 2000;46:182-9
   Web of Science ®Google Scholar
• Edelstein SL, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 1997;46:701-10
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Ghushchyan V. Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample Med Decis Making 2006;26:401-9
   PubMed Web of Science ®Google Scholar
• Echouffo-Tcheugui JB, Simmons RK, Williams KM, et al. The ADDITION-Cambridge trial protocol: a cluster randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients. BMC Public Health 2009;9:136
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20:S5-S26
   PubMed Web of Science ®Google Scholar
• Coffey JT, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002;25:2238-43
   PubMed Web of Science ®Google Scholar
• Herman WH, Hayes AJ, Leal J, et al. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 2013;56:1925-33
   PubMed Web of Science ®Google Scholar
• Toscano CM, Duncan BB, Mengue SS, et al. Initial impact and cost of a nationwide population screening campaign for diabetes in Brazil: a follow up study. BMC Health Serv Res 2008;8:189
   PubMed Web of Science ®Google Scholar
• Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735-44
   PubMed Web of Science ®Google Scholar
• Schlessinger L, Eddy DM. Archimedes: a new model for simulating health care systems-the mathematical formulation. J Biomed Inform 2002;35:37-50
   PubMed Web of Science ®Google Scholar
• Walker A, Colagiuri S, McLennan M. Cost-benefit model of diabetes prevention and care: model construction, assumptions and validation. Technical Paper. Canberra: NATSEM, May 2003. Available at: http://www.natsem.canberra.edu.au/publications/?publication=cost-benefit-model-of-diabetes-prevention-and-care-model-construction-assumptions-and-validation [Last accessed 29 October 2016]
   Google Scholar
• Gillett M, Chilcott J, Goyder E, et al. Prevention of type 2 diabetes: risk identification and interventions for individuals at high risk – economic review and modelling. Sheffield: ScHARR Public Health Collaborating Centre, 2012. Available at: https://www.nice.org.uk/guidance/ph38/evidence/he1-costeffectiveness-review-and-economic-modelling-2 [Last accessed 29 October 2016]
   Google Scholar
• Vanderwood KK, Kramer MK, Miller RG, et al. Evaluation of non-invasive screening measures to identify individuals with prediabetes Diabetes Res Clin Pract 2015;107:194-201
   PubMed Web of Science ®Google Scholar
• Waugh NR, Shyangdan D, Taylor-Phillips S, et al. Screening for type 2 diabetes: a short report for the National Screening Committee. Health Technol Assess 2013;17:1-89
   PubMed Web of Science ®Google Scholar
• Mission JF, Ohno MS, Cheng YW, Caughey AB. Gestational diabetes screening with the new IADPSG guidelines: a cost-effectiveness analysis. Am J Obstet Gynecol 2012;326:e321-9
   Google Scholar
• Round JA, Jacklin P, Fraser RB, et al. Screening for gestational diabetes mellitus: cost–utility of different screening strategies based on a woman’s individual risk of disease. Diabetologia 2011;54:256-63
   PubMed Web of Science ®Google Scholar
• Werner EF, Pettker CM, Zuckerwise L, et al. Screening for gestational diabetes mellitus: are the criteria proposed by the international association of the Diabetes and Pregnancy Study Groups cost-effective? Diabetes Care 2012;35:529-35
   PubMed Web of Science ®Google Scholar
• Llewellyn A, Simmonds M, Owen CG, Woolacott N. Childhood obesity as a predictor of morbidity in adulthood: a systematic review and meta-analysis. Obes Rev 2016;17:56-67
   PubMed Web of Science ®Google Scholar
• Hannon TS, Arslanian SA. The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes. Ann N Y Acad Sci 2015;1353:113-37
   PubMed Web of Science ®Google Scholar